Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
IPO Year: 2019
Exchange: NASDAQ
Website: adaptivebiotech.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2025 | $15.00 | Buy | Craig Hallum |
| 3/21/2025 | $9.00 | Neutral → Buy | Goldman |
| 7/5/2023 | $15.00 | Overweight | JP Morgan |
| 1/5/2023 | $15.00 | Sector Outperform | Scotiabank |
| 12/21/2022 | $7.50 → $14.00 | Neutral → Overweight | Piper Sandler |
| 8/25/2022 | $8.00 | Underperform | Credit Suisse |
| 6/3/2022 | $7.50 | Neutral | Piper Sandler |
| 2/16/2022 | $40.00 → $32.00 | Buy | BofA Securities |
| 2/16/2022 | $75.00 → $50.00 | Overweight | JP Morgan |
| 2/16/2022 | $54.00 → $21.00 | Neutral | Goldman |
Cohen to serve as Chair of the Audit Committee Grindr Inc. (NYSE:GRND), the Global Gayborhood in Your Pocket™, today announced the appointment of Chad Cohen, former Chief Financial Officer of Zillow Group Inc. (NASDAQ:Z) and Adaptive Biotechnologies Corp. (NASDAQ:ADPT) and Founding Partner of Scala Advisors, LLC, to Grindr's Board of Directors as of June 3, 2025. Cohen was also appointed to serve as the Chair of Grindr's Audit Committee. A seasoned public company finance executive and board member, Cohen has helped grow several multi-billion dollar technology companies, including multiple leading consumer Internet brands. Prior to his current role, Cohen served as the Chief Financial Of
SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Tycho Peterson as chief financial officer (CFO). Mr. Peterson brings several decades of financial leadership and experience within the life science and diagnostic industries. "Tycho has been a leader in this space over the last two decades, during which disruptive technologies such as genomic sequencing and artificial intelligence have driven a complete paradigm shift in diagnostics and precision medic
SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately. Nitin brings more than 15 years of proven commercial experience at leading life sciences and diagnostics companies, most recently at Guardant Health. "Adaptive has set the stage for commercial success with well-defined growth strategies and a solid pipeline for our current research and diagnostic products. Nit
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. "We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "This performance highlights the scalability of our MRD business and the growing momentum behind it. As a resul
SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours
SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. "2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and advancements in our Immune Medicine programs. Our MRD revenue grew by 42%, with a 35% increase in clonoSEQ test volume, and we nominated a lead autoimmune indication within our Immune Medicine business," said Chad
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 11, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for repl
SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2024. "Our focus on execution and disciplined capital allocation are driving MRD growth with a clear path to profitability while we continue to advance our targeted Immune Medicine programs," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "The increased clonoSEQ® Medicare Gapfill rate and the extensio
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 ho
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024. "We had another strong quarter with MRD revenue growth of 36% and delivered significant reductions in operating spend and cash burn versus prior year," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "I am encouraged by our progress towards MRD profitability and our execution on key Immune Medicine prog
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hou
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2024. "This quarter, we implemented important decisions to maximize the value of our MRD and Immune Medicine businesses. I am confident in the steps we are taking to execute on their respective priorities with separate segment reporting," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "Our cash position is s
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours a